利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

45 条记录 (耗时 0.035 秒)

    5,6,Fused Pyrrolidine Compounds Useful as Tachykinin Receptor Antagonists
    2.
    发明申请
    5,6,Fused Pyrrolidine Compounds Useful as Tachykinin Receptor Antagonists 审中-公开
    5,6，用作速激肽受体拮抗剂的熔融吡咯烷化合物

    公开(公告)号：US20090286777A1

    公开(公告)日：2009-11-19

    申请号：US12226294

    申请日：2007-05-11

    申请人： Jianming Bao ,  Robert J. DeVita ,  Sander G. Mills ,  Gregori J. Morriello

    发明人： Jianming Bao ,  Robert J. DeVita ,  Sander G. Mills ,  Gregori J. Morriello

    IPC分类号： A61K31/437 ,  C07D471/04 ,  A61K31/5377 ,  A61K31/506

    CPC分类号： C07D471/04

    摘要： The present invention is directed to certain 5,6-fused pyrrolidine compounds which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including emesis, urinary incontinence, depression, and anxiety.

    摘要翻译： 本发明涉及可用作神经激肽-1（NK-1）受体拮抗剂的某些5,6-稠合的吡咯烷化合物，以及速激肽抑制剂，特别是物质P。本发明还涉及包含这些化合物的药物制剂 作为活性成分以及化合物及其制剂在治疗某些疾病（包括呕吐，尿失禁，抑郁和焦虑）中的用途。

    Hydroxymethyl ether hydroisoindoline tachykinin receptor antagonists
    5.
    发明授权
    Hydroxymethyl ether hydroisoindoline tachykinin receptor antagonists 有权
    羟甲醚加氢异吲哚啉速效肽受体拮抗剂

    公开(公告)号：US08124633B2

    公开(公告)日：2012-02-28

    申请号：US12593168

    申请日：2008-04-07

    申请人： Robert J. DeVita ,  Sander G. Mills ,  Jinlong Jiang ,  Andrew J. Kassick ,  Jianming Bao

    发明人： Robert J. DeVita ,  Sander G. Mills ,  Jinlong Jiang ,  Andrew J. Kassick ,  Jianming Bao

    IPC分类号： A61K31/422 ,  C07D209/02

    CPC分类号： C07D209/44 ,  C07D413/04

    摘要： The present invention is directed to certain hydroxymethyl ether hydroisoindoline compounds which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including emesis, urinary incontinence, LUTS, depression, and anxiety.

    摘要翻译： 本发明涉及某些可用作神经激肽-1（NK-1）受体拮抗剂，速激肽抑制剂，特别是物质P的羟甲基醚异二氢吲哚化合物。本发明还涉及包含这些化合物作为活性成分的药物制剂 以及化合物及其制剂在治疗某些疾病（包括呕吐，尿失禁，LUTS，抑郁和焦虑）中的用途。

    6.5 -PYRROLOPIPERIDINE TACHYKININ RECEPTOR ANTAGONISTS
    6.
    发明申请
    6.5 -PYRROLOPIPERIDINE TACHYKININ RECEPTOR ANTAGONISTS 审中-公开
    6.5-吡罗昔芬TACHYKININ受体拮抗剂

    公开(公告)号：US20100197724A1

    公开(公告)日：2010-08-05

    申请号：US12665088

    申请日：2008-06-18

    申请人： Jianming Bao ,  Robert J. DeVita ,  Huagang Lu

    发明人： Jianming Bao ,  Robert J. DeVita ,  Huagang Lu

    IPC分类号： A61K31/437 ,  C07D471/04 ,  A61P25/00 ,  A61P29/00 ,  A61P25/06 ,  A61P1/08 ,  A61P25/24 ,  A61P25/22

    CPC分类号： C07D471/04

    摘要： The present invention is directed to certain hydroxymethyl ether hydroisoindoline compounds which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including emesis, urinary incontinence, LUTS, depression, and anxiety.

    摘要翻译： 本发明涉及某些可用作神经激肽-1（NK-1）受体拮抗剂，速激肽抑制剂，特别是物质P的羟甲基醚异二氢吲哚化合物。本发明还涉及包含这些化合物作为活性成分的药物制剂 以及化合物及其制剂在治疗某些疾病（包括呕吐，尿失禁，LUTS，抑郁和焦虑）中的用途。

    Substituted 3-alkyl and 3-alkenyl azetidine derivatives
    8.
    发明授权
    Substituted 3-alkyl and 3-alkenyl azetidine derivatives 失效
    取代的3-烷基和3-烯基氮杂环丁烷衍生物

    公开(公告)号：US07906503B2

    公开(公告)日：2011-03-15

    申请号：US12288518

    申请日：2008-10-21

    申请人： Robert K. Baker ,  Jianming Bao ,  Shouwu Miao ,  Kathleen M. Rupprecht

    发明人： Robert K. Baker ,  Jianming Bao ,  Shouwu Miao ,  Kathleen M. Rupprecht

    IPC分类号： A61K31/397 ,  A61K31/4427 ,  A61K31/4178 ,  A61K31/4196 ,  C07D205/04 ,  C07D401/06 ,  C07D205/06 ,  C07D403/06

    CPC分类号： C07D205/04 ,  C07D205/06 ,  C07D401/06 ,  C07D403/06 ,  C07D403/10 ,  C07D405/06 ,  C07D409/06

    摘要： Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

    摘要翻译： 结构式（I）的新型化合物是大麻素-1（CB1）受体的拮抗剂和/或反向激动剂，可用于治疗，预防和抑制由CB1受体介导的疾病。 本发明的化合物可用作治疗精神病，记忆缺陷，认知障碍，偏头痛，神经病，包括多发性硬化和神经 - 巴利综合征的神经炎症性疾病以及病毒性脑炎的炎症性后遗症，脑血管 事故和头部创伤，焦虑症，压力，癫痫，帕金森病，运动障碍和精神分裂症。 这些化合物还可用于治疗药物滥用障碍，治疗肥胖或进食障碍，以及治疗哮喘，便秘，慢性肠假性梗阻和肝硬化。